Enzolytics Inc
Change company Symbol lookup
Select an option...
ENZC Enzolytics Inc
SMSMY Sims Ltd
DHCAU DHC Acquisition Corp
BCH Banco de Chile
NLRCF Northern Lights Resources Corp
ABM ABM Industries Inc
LVOXW LiveVox Holding Equity Warrants Exp 18 June 2026 *W EXP 06/18/2026
TY- Tri-Continental Corp
BAC Bank of America Corp
KLXE KLX Energy Services Holdings Inc
Go

Company profile

Enzolytics, Inc. is a drug development biotechnology company. The Company is engaged in the commercialization of its proteins for the treatment of debilitating infectious diseases. The Company is focused in developing monoclonal antibody therapy and treating infectious diseases. It has anti-HIV therapeutics and a methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The Company has clinically tested anti-HIV therapeutics. The Company has developed a cell line that produces fully human monoclonal antibodies that target and neutralizes the HIV virus. The Company has also created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus, and diphtheria. The Company is testing these antibodies to prepare them for use as therapies against these diseases.

Closing Price
$0.069
Day's Change
0.003 (4.55%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.0698
Day's Low
0.0627
Volume
(Average)
Volume:
5,002,289

10-day average volume:
4,736,200
5,002,289

Display:

Providers:

UpdateCancel
6 providers
June 21, 2022
Enzolytics Announces the Discovery of Conserved Target Sites on the Monkeypox Virus

COLLEGE STATION, TX / ACCESSWIRE / June 21, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (ENZC" or the "Company") today announced it has identified conserved, immutable sites (epitopes) on the Monkeypox virus. These discoveries are a part of Enzolytics...(Accesswire)

May 16, 2022
Enzolytics, Inc. Discusses the Significance and Revenue Potential of Its Therapeutic Platforms with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - May 16, 2022) - The Stock Day Podcast welcomed Enzolytics, Inc. (ENZC) ("the Company"), a drug development company committed to commercializing its proprietary proteins and monoclonal antibodies to treat...(Newsfile)

April 25, 2022
CORRECTION: Enzolytics, Inc. Reports Progress and Future Plans

This version includes the Safe Harbor statement that was missing from the previous version of this release. COLLEGE STATION, TX / ACCESSWIRE / April 25, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).(Accesswire)

Enzolytics, Inc. Reports Progress and Future Plans

COLLEGE STATION, TX / ACCESSWIRE / April 25, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Enzolytics continues to make significant progress in its multiple therapeutic platforms and outlines here the technical aspects of the...(Accesswire)

April 11, 2022
Enzolytics IPF Immune(TM) Introduced to Large and Small Retail Buyers at Recent ECRM "Weight Management, Nutrition, and Vitamin Program"

COLLEGE STATION, TX / ACCESSWIRE / April 11, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Large and small retail buyers were introduced to Enzolytics IPF ImmuneT, an immune modulator that debuted at ECRM's "Weight Management...(Accesswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.